NPM1 MRD Analysis
Also known as: NPM1 Minimal Residual Disease
Use
Mutation at exon 12 of nucleophosmin 1 (NPM1) gene is a predictor of favorable prognosis in AML with intermediate-risk and associated with good response to induction chemotherapy; if there is no mutation in FLT3. Mutations in the NPM1 gene also are frequently associated with normal karyotype in adult and pediatric acute myeloid leukemia (AML). The ratio of the mutant peak to total can be used to monitor disease and response to therapy.
Special Instructions
For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Paraffin block is preferred for FFPE samples. If submitting slides, ensure positively-charged slides and 10% NBF fixative are used.
Limitations
Testing is performed on plasma with a PCR modification to improve sensitivity. The lower limit of detection of mutated NPM1 in this assay is 5 x 10-3 (0.5%). Positive results are reported quantitatively if the percentage of mutated DNA is >1%, and they are reported qualitatively if <1%.
Methodology
PCR-based (qPCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube
Storage Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.